Literature DB >> 2579174

Neovascularization produced by angiotensin II.

L A Fernandez, J Twickler, A Mead.   

Abstract

Following vascular occlusion, development of collateral circulation occurs in at least two time-related phases: (1) the fast enhancement of the function of preexisting channels and (2) the slow formation of new vessels. Inasmuch as the renin-angiotensin system can act as a protective mechanism against local ischemia by activating preexisting collateral vessels, it is of interest to establish whether angiotensin II also produces stimulation of new vessel formation. Angiotensin II or cholecystokinin, an unrelated peptide, was incorporated in a slow-release formulation polyacrylamide gel and implanted in a pocket made in the rabbit cornea. Periodic examinations revealed that angiotensin II significantly stimulates new vessel formation; maximum values were attained in approximately 2 to 3 weeks. In contrast, cholecystokinin or polyacrylamide gel alone failed to stimulate any significant new vessel formation. Positive neovascularization was present in 85% of the total number of corneas implanted with angiotensin II, whereas 14% and 8% positive results were seen in the corneas implanted with either cholecystokinin or polyacrylamide gel alone, respectively. It is concluded that angiotensin II not only facilitates the activation of preexisting collateral vascular pathways but also has angiogenic properties and therefore could play an active role not only in the fast but also in the slow phase of the development of collateral circulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579174

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  69 in total

Review 1.  Ovarian hyperstimulation syndrome: a review of pathophysiology.

Authors:  P A Bergh; D Navot
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

2.  Role of the renin angiotensin system on bone marrow-derived stem cell function and its impact on skeletal muscle angiogenesis.

Authors:  Micheline M de Resende; Timothy J Stodola; Andrew S Greene
Journal:  Physiol Genomics       Date:  2010-05-25       Impact factor: 3.107

3.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy.

Authors:  M Larsen; E Hommel; H H Parving; H Lund-Andersen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

5.  Distortion of maternal-fetal angiotensin II type 1 receptor allele transmission in pre-eclampsia.

Authors:  L Morgan; S Crawshaw; P N Baker; J F Brookfield; F Broughton Pipkin; N Kalsheker
Journal:  J Med Genet       Date:  1998-08       Impact factor: 6.318

6.  Angiotensins stimulate in vitro ovulation and contraction of brook trout (Salvelinus fontinalis) follicles.

Authors:  S Y Hsu; F W Goetz
Journal:  Fish Physiol Biochem       Date:  1992-12       Impact factor: 2.794

7.  Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.

Authors:  George A Makar; John H Holmes; Yu-Xiao Yang
Journal:  J Natl Cancer Inst       Date:  2014-01-15       Impact factor: 13.506

8.  Postnatal renal development of rats from mothers that received increased sodium intake.

Authors:  Ana Paula C Balbi; Roberto S Costa; Terezila M Coimbra
Journal:  Pediatr Nephrol       Date:  2004-08-28       Impact factor: 3.714

9.  Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM.

Authors:  S Mäkimattila; P Summanen; I Matinlauri; M Mäntysaari; A Schlenzka; M Aalto; K Irjala; H Yki-Järvinen
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

10.  Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system.

Authors:  J Wagner; A H Jan Danser; F H Derkx; T V de Jong; M Paul; J J Mullins; M A Schalekamp; D Ganten
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.